Leqvio Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

Concise Prescribing Info

Contents

Inclisiran

Indications/Uses

Adults w/ primary hypercholesterolaemia (heterozygous familial & non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination w/ a statin or statin w/ other lipid-lowering therapies in patients unable to reach LDL-C goals w/ max tolerated statin dose; or alone or in combination w/ other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated.

Click to view Leqvio detailed prescribing information

Dosage/Direction for Use

Initially 284 mg administered as a single SC inj, again at 3 mth, followed by every 6 mth.

Click to view Leqvio detailed prescribing information

Overdosage

View Leqvio overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Leqvio detailed prescribing information

Special Precautions

Inj should not be given into areas of active skin disease or injury eg, sunburns, skin rashes, inflammation or skin infections. Haemodialysis should not be performed for at least 72 hr after inclisiran dosing. Caution in patients w/ severe hepatic impairment (Child-Pugh class C); severe renal impairment. Avoid use during pregnancy. Discontinue breast-feeding or discontinue/abstain from therapy. Safety & efficacy in childn <18 yr have not yet been established.

Click to view Leqvio detailed prescribing information

Use In Pregnancy & Lactation

Click to view Leqvio detailed prescribing information

Adverse Reactions

Adverse reactions at the inj site.

Click to view Leqvio detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Leqvio detailed prescribing information

Storage

View Leqvio storage conditions for details to ensure optimal shelf-life.

Description

View Leqvio description for details of the chemical structure and excipients (inactive components).

Action

View Leqvio mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Dyslipidaemic Agents

ATC Classification

C10AX16 - inclisiran ; Belongs to the class of other lipid modifying agents.

Regulatory Classification

P₁S₁S₃

Presentation/Packing

Form

Leqvio soln for inj 284 mg/1.5 mL

Packing/Price

1's

Leqvio

inclisiran

Manufacturer:

Novartis

Distributor:

Zuellig